Experts unite to fix how cancer trials measure success
NCT ID NCT03676010
First seen Jan 04, 2026 · Last updated May 05, 2026 · Updated 18 times
Summary
This study brings together 265 experts to create clear, consistent definitions for key time-to-event endpoints in cancer clinical trials, such as progression-free survival. By standardizing these definitions across different cancer types, researchers hope to make trial results easier to compare and more reliable. The project focuses on several cancers including breast, pancreatic, and colon cancer, but does not involve any direct treatment or patient intervention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Georges François Leclerc
Dijon, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut du Cancer de Montpellier
Montpellier, France
Conditions
Explore the condition pages connected to this study.